- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Alliance Pharmaceutical responds to FDA
The San Diego developer of the ultrasound contrast medium Imavist has provided documentation requested by the FDA to support the companyπs application to market the agent in the U.S. The FDA had reviewed a new drug application for Imavist and found
The San Diego developer of the ultrasound contrast medium Imavist has provided documentation requested by the FDA to support the companyπs application to market the agent in the U.S. The FDA had reviewed a new drug application for Imavist and found it to be approvable upon satisfactory response to issues identified in the review process. Alliance and Schering of Germany are developing Imavist jointly. Alliance believes the current submission fully addresses the issues noted by the FDA, and the company hopes to receive final approval later this year.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
MRI-Based AI Model Shows Promise in Predicting Lymph Node Metastasis with Breast Cancer
April 15th 2024For the prediction of axillary lymph node metastasis in patients with breast cancer, an MRI-based, 4D convolutional neural network model demonstrated an AUC of 87 percent and sensitivity of 89 percent, according to new research.
